Answer
Dinutuximab beta induces complement-dependent cytotoxicity (CDC) and antibody-dependent cell-mediated cytotoxicity (ADCC) in vitro against GD2-expressing neuroblastoma cells.
Sources for this answer
- Qarziba (Dinutuximab beta)Recordati UK Ltd · emc · SmPC §5.1 Pharmacodynamic properties · Version 13Document updated
Sources checked